Dr. Markus Rudin Joins VisEn Medical's Scientific Advisory Board; University ETH Zurich Adopts VisEn's FMT(TM) System and Fluorescence Probe Platforms to Advance Molecular Imaging From Research Through Medicine.

WOBURN, Mass. -- VisEn Medical, a leader in fluorescence technologies for in vivo imaging of biologic and molecular processes, today announced that Dr. Markus Rudin has joined its Scientific Advisory Board.

Dr. Rudin is Professor of Molecular Imaging and Functional Pharmacology at both the University of Zurich and the ETH Zurich (Swiss Federal Institute of Technology), Switzerland, and formerly head of Imaging Technologies at Novartis.

In a related announcement, VisEn Medical also reported that Dr. Rudin's laboratory at University ETH has adopted VisEn's portfolio of in vivo Fluorescence Probes and Fluorescence Molecular Tomography (FMT(TM)) imaging system, as cornerstones of their molecular imaging programs. VisEn's fluorescence imaging technologies and products are designed to provide the industry's most robust and accurate imaging performance in identifying, characterizing and quantifying a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease and bone disease. By imaging these disease-related biologic activities in vivo, VisEn's technology platforms enable expanded areas of research and more efficient drug development. They are also designed for expansion into biologic imaging in the emerging field of personalized medicine.

Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement, "Dr. Rudin's deep scientific heritage and guiding role in molecular imaging has been one of the pioneering forces of the whole field, first in drug development with Novartis, and now in industry-leading research with ETH. Our work with Dr. Rudin over the years has been an important factor in shaping our technology platforms to date, and his further role as an advisor to VisEn will help drive our technologies and the field of molecular imaging forward. We are honored by his participation with VisEn and see this as yet another key foundation for our company's leadership."

Dr. Rudin added, "Real-time imaging of biologic and molecular processes in vivo is playing an increasingly central role in basic research and drug development today. VisEn's FMT imaging system and probe platforms were developed in close collaboration with leading researchers, pharmaceutical companies and clinicians. The result is an unprecedented level of biologically-relevant data specificity and quantification, that together, will propel this area from basic research and pre-clinical imaging studies today and pave the way to the future of personalized medicine. I look forward to collaborating even more deeply with VisEn's Scientific Advisory Board and management on the future of this promising area of research."

Prior to his academic career, Dr. Rudin was head of an MR imaging lab and later head of the Biophysics Group at Sandoz AG. In 1996, he became head of the In-vivo Models Unit and in 2000 head of the Analytical and Imaging Science Unit within Discovery Technologies at the Novartis Institutes for Biomedical Research.

About VisEn's Products

VisEn's fluorescence probe portfolio harnesses the power of fluorescent labeling technology for in vivo molecular imaging. They are designed to target and read out various disease-related molecular activities in vivo, including protease activity, angiogenesis, vascular permeability and bone turnover. VisEn's FMT(TM) system provides true quantification of fluorescence within the living animal. Together, the fluorescence probes and FMT(TM) system can be used to observe and quantify a range of biological phenomena in vivo, including molecular activities in disease states such as cancer, inflammation, cardiovascular disease and bone disease.

About VisEn Medical, Inc.

VisEn Medical, Inc. is developing today's leading fluorescence molecular imaging technology platforms, from research through medicine. The Company's products enable in vivo imaging of biological and molecular processes, and are targeted to the imaging of central disease states including protease activity, oncology, bone growth, cardiovascular disease and inflammation. VisEn also works with its partners to design tailored probes and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group. For further information please visit www.visenmedical.com.